This clinical trial is focused on studying a type of blood cancer called Chronic Myeloid Leukemia (CML), specifically in its chronic phase. The study is testing a new medication called Olverembatinib, also known by its code name HQP1351, to see how well it works compared to an existing treatment called Bosutinib. Both medications are taken as tablets by mouth. The purpose of the study is to compare the effectiveness of Olverembatinib with Bosutinib in achieving a significant reduction in cancer cells in the blood, known as a major molecular response, over a period of 24 weeks.

The study is divided into two parts. In the first part, participants will be randomly assigned to receive either Olverembatinib or Bosutinib to compare their effects. In the second part, the focus will be on patients with a specific genetic change in their cancer cells, known as the T315I mutation, to evaluate how well Olverembatinib works for them. The study will last for up to 48 weeks, with regular check-ups to monitor the response to the treatment and any side effects. Participants will be closely observed to ensure their safety and to gather information on how the treatments affect their health and quality of life.

This trial aims to provide valuable insights into the potential benefits of Olverembatinib for patients with chronic phase CML, especially those who have not responded well to other treatments. The findings could help improve treatment options for this type of leukemia, offering hope for better management of the disease.